A short peptide derived from a protein in human gastric juice, and one of the most searched healing peptides online. Dozens of rat studies show faster repair of tendons, muscle, gut, and blood vessels, but human evidence amounts to three tiny pilot reports, and the FDA has flagged compounded versions as a safety risk. The first placebo-controlled human trial began recruiting in 2026.
BPC-157 is a synthetic copy of a fragment of a protective protein found in human gastric juice. In animal and cell studies it activates several overlapping repair pathways: the VEGF receptor that drives new blood vessel growth, nitric oxide production through the Akt and eNOS pathway, and the ERK signaling that controls cell growth. The result in injured rats is more blood supply, more fibroblast activity, and stabilized nerve-muscle connections, which matters most in poorly vascularized tissue like tendons. It also raises growth hormone receptor expression and lowers inflammatory cytokines in these models.
Injected near injury (1/7)
BPC-157, a fragment of a protective protein in gastric juice, is injected near an injury.
In the only study on human tissue, rings of internal mammary artery taken during bypass surgery relaxed in a dose-dependent way when exposed to the peptide, mostly through endothelial nitric oxide. In animals the peptide is metabolized in the liver, has a half-life under 30 minutes, and is cleared by the kidneys. A preclinical safety program in mice, rats, rabbits, and dogs found no serious toxicity, no genetic damage, and no harm to embryos, with only a drop in creatinine in dogs at 2 mg per kilogram. Whether any of this biology happens in a person who injects it has not been shown.
BPC-157 is sold online and by compounders for tendon, ligament, and muscle injuries, gut problems, and recovery from almost anything. In animal models it speeds healing of transected tendons and muscle, ligament injuries, fractures, gut lesions, and blood vessels, and a 2025 systematic review found 35 preclinical studies against a single clinical one. The human reports are a retrospective survey of 16 knee pain patients, a pilot study of 12 women with interstitial cystitis treated with bladder injections, and a 2-person intravenous safety study. The World Anti-Doping Agency bans it, and the FDA has not approved it for anything.
People inject it under the skin near an injury, take it by mouth, or receive it from clinics as joint injections, following protocols that have never been tested in a controlled trial. A phase 2 trial for acute hamstring strains, with 14 days of treatment on top of rehabilitation, began recruiting in 2026 and is the first placebo-controlled human study. The FDA lists compounded BPC-157 among substances that may present significant safety risks and will discuss it at an advisory committee meeting in July 2026. Regulators in Australia and Canada name it among unapproved injectable peptides promoted online.
A 2025 systematic review found 36 studies, 35 preclinical and 1 clinical, with consistent improvements in animal muscle, tendon, ligament, and bone injury models. The human record is a chart review in which 11 of 12 patients given knee injections reported relief, a 12-woman bladder pilot in which all reported symptom resolution, and a 2-person intravenous study with normal blood tests afterward. None was blinded, randomized, or controlled, and two were run at the same private clinic. A 2015 oral safety study in healthy volunteers in Mexico lists no results.
The biggest unknown is whether a standardized BPC-157 product can show benefit in a controlled human trial, which the 2026 hamstring study will be the first to test. Product identity is a separate problem, since the material in rat studies, the compounded peptide, and internet vials have never been shown to match. Long-term safety, immune reactions, and dosing in people are unmeasured. Until the trial reports, every human claim rests on animals or on uncontrolled reports.
Human side effect data are almost nonexistent, and the three pilot reports describe no adverse events in a combined 30 people. The FDA says compounded BPC-157 may pose an immunogenicity risk for some routes, has peptide impurity and characterization problems, and comes with little or no safety information, so the agency cannot judge whether it would harm people. Because it acts on growth and blood vessel pathways, long-term effects are unknown, and no study has followed users over time. Unregulated vials add risks of contamination, infection, and unknown dose.
No regulator has approved this compound, and no company is seeking approval.
BPC-157 is not approved by the FDA or any other regulator. The FDA lists compounded drugs containing BPC-157 among bulk substances that may present significant safety risks, citing immunogenicity, peptide impurities, and limited safety information, and its Pharmacy Compounding Advisory Committee is scheduled to discuss BPC-157 free base and acetate on July 23, 2026. The World Anti-Doping Agency prohibits BPC-157 as a non-approved substance. Australia's TGA and Health Canada both name it among unapproved injectable peptides sold online.